Ornithine decarboxylase

Orphan designation: Eflornithine Treatment of neuroblastoma, 27/09/2011 Withdrawn

Retrieved on: 
Tuesday, April 9, 2024
Eurostat, Diagnosis, Civil service commission, Radiation, Brain, Ornithine decarboxylase, Enzyme, Growth, Weakness, Survival, Cell, Neuroblastoma, Disease, Patient, Tablet, Committee, Knowledge, Abdomen, Regulation, Child, Cancer, EMA, IRIS, Bone pain, Mouth, European, Polyamine, Fever, COMP, Sponsor, European Commission, Spine, Safety, Marketing, Limited, Medicine, Pharmaceutical industry

Orphan designation: Eflornithine Treatment of neuroblastoma, 27/09/2011 Withdrawn

Key Points: 


Orphan designation: Eflornithine Treatment of neuroblastoma, 27/09/2011 Withdrawn

Panbela Announces Publication of Preclinical and Clinical Data Titled: Inhibition of Polyamine Biosynthesis Preserves β Cell Function in Type 1 Diabetes

Retrieved on: 
Thursday, November 2, 2023
Survival, PBLA, Indiana University School of Medicine, Health, JDRF, Therapy, Hope, Mortality, MD, Pathology, Doctor of Philosophy, Disease, Research, Observation, Pediatrics, Riley Children's Foundation, News, Quality of life, Polyamine, School, Risk, Putrescine, University, U.S. News & World Report, ODC, Indiana University, Patient, MSN, Ornithine decarboxylase, DFMO, Pharmaceutical industry, Vaccine, Eflornithine, Medicine, T1D

A Phase 1 clinical study showed that DFMO treatment may provide metabolic benefits to preserve β cell function and health in T1D.

Key Points: 
  • A Phase 1 clinical study showed that DFMO treatment may provide metabolic benefits to preserve β cell function and health in T1D.
  • Data published in the journal Cell Reports Medicine investigated the mechanism of polyamines and polyamine inhibition by CPP-1X on β cell stress that plays a role in the onset of type 1 diabetes in in vitro and ex vivo models.
  • Results showed that DFMO treatment may preserve β cell function, reflected by C-peptide levels in patients with T1D through the modulation of urinary polyamines, in particular putrescine.
  • Results from these studies suggest that CPP-1X is a safe, oral treatment option that may improve β cell function and/or survival in recent onset T1D.

Panbela Announces Poster Presentation at the Endocrine Society Meeting: Polyamine Inhibition and β-Cell Preservation in Recent Onset Type 1 Diabetes

Retrieved on: 
Monday, June 26, 2023
IU, JDRF, Indiana University, University, Therapy, Diabetes, MSN, Polyamine, Survival, PBLA, Research, Cell, RNA, Doctor of Philosophy, Proteomics, Incidence, Indiana University School of Medicine, Patient, Antigen presentation, ODC, Reactive oxygen species, DFMO, School, Endocrine Society, Mouse, Poster, Ornithine decarboxylase, Pharmaceutical industry, Vaccine, T1D, Eflornithine, Medicine

The research is part of a multi-site clinical trial led by Indiana University School of Medicine, supported by funding from JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization.

Key Points: 
  • The research is part of a multi-site clinical trial led by Indiana University School of Medicine, supported by funding from JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization.
  • Panbela Therapeutics is providing the drug at no cost to researchers and was not involved in the design and analysis of these studies.
  • In the Phase 1 dose range finding study of in patients with recent onset T1D, CPP-1X was well tolerated and a dose dependent inhibition of ODC was observed.
  • Results from these studies suggest that CPP-1X is a safe, oral treatment option that may improve β cell function and/or survival in recent onset T1D.

Panbela Announces Poster Presentation at Immunology of Diabetes Society Meeting: Evaluating the Potential of CPP-1X (Eflornithine) in Recent Onset Type 1 Diabetes

Retrieved on: 
Thursday, June 1, 2023
IU, JDRF, Mouse, Indiana University, University, Therapy, Diabetes, MSN, T1D, Polyamine, Survival, PBLA, Research, Doctor of Philosophy, IDS, Incidence, Indiana University School of Medicine, Patient, ODC, DFMO, School, Poster, Immunology, Ornithine decarboxylase, Pharmaceutical industry, Vaccine, Medicine, Eflornithine

The research is part of a multi-site clinical trial led by Indiana University (IU) School of Medicine, supported by funding from JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization.

Key Points: 
  • The research is part of a multi-site clinical trial led by Indiana University (IU) School of Medicine, supported by funding from JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization.
  • Panbela Therapeutics is providing the drug at no cost to researchers and was not involved in the design and analysis of these studies.
  • Results from these studies suggest that CPP-1X is a safe, oral treatment option that may improve β cell function and/or survival in recent onset T1D.
  • Details of the presentation are as follows:
    Additional meeting information can be found on the IDS website: https://www.idsparis2023.com/_files/ugd/d65629_717d6a377fae45dc95b0ebb26...

Ornithine Decarboxylase (ODC) Inhibitor Pipeline Insight Report 2022 Featuring Orbus Therapeutics, Aminex Therapeutics, Genzyme, Nippon Kayaku, & Cancer Prevention Pharmaceuticals - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 29, 2022
Biotechnology, Pharmaceutical, Oncology, General Health, Health, Chemicals, Plastics, Manufacturing, Clinical Trials, Ornithine decarboxylase, Therapy, Precision medicine, ODC, Pharmaceutical industry

The "Ornithine Decarboxylase (ODC) Inhibitor - Pipeline Insight, 2022" clinical trials have been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Ornithine Decarboxylase (ODC) Inhibitor - Pipeline Insight, 2022" clinical trials have been added to ResearchAndMarkets.com's offering.
  • "Ornithine Decarboxylase (ODC) Inhibitor - Pipeline Insight, 2022" offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Ornithine Decarboxylase (ODC) Inhibitor development.
  • The report assesses the active Ornithine Decarboxylase (ODC) Inhibitor pipeline products by developmental stage, product type, molecule type, and administration route.
  • Identify the product attributes and use it for target finding, drug repurposing, and precision medicine

Orbus Therapeutics’ Phase 3 Eflornithine STELLAR Study Reaches Full Patient Enrollment

Retrieved on: 
Wednesday, January 19, 2022
Survival, Anaplastic astrocytoma, Ornithine decarboxylase, Safety, Overalls, EMA, European Medicines Agency, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Population, Lomustine, Achievement, CEO, Efficacy, GLOBE, Committee, Radiation, Isocitrate dehydrogenase, Glioma, Irradiation, IDH, PALO, Committee for Medicinal Products for Human Use, PFS, Therapy, Company, European Directive on Traditional Herbal Medicinal Products, Neuron, Cancer, OS, Food, CHMP, FDA, Brain, Prevalence, Trial of the century, ORR, Pharmaceutical industry, Medical imaging, Eflornithine, Patient

PALO ALTO, Calif., Jan. 19, 2022 (GLOBE NEWSWIRE) -- Orbus Therapeutics Inc., a private, late-stage biopharmaceutical company focused on the development and commercialization of therapies that treat rare diseases, today announced that patient enrollment of its Phase 3 STELLAR clinical study of eflornithine in patients with recurrent anaplastic astrocytoma is complete. The STELLAR study completed full enrollment with a total of 343 patients.

Key Points: 
  • PALO ALTO, Calif., Jan. 19, 2022 (GLOBE NEWSWIRE) -- Orbus Therapeutics Inc., a private, late-stage biopharmaceutical company focused on the development and commercialization of therapies that treat rare diseases, today announced that patient enrollment of its Phase 3 STELLAR clinical study of eflornithine in patients with recurrent anaplastic astrocytoma is complete.
  • The STELLAR study completed full enrollment with a total of 343 patients.
  • We are delighted to announce that we have completed enrollment of patients in the STELLAR study.
  • The STELLAR study is the largest randomized Phase 3 study that has been conducted in this patient population, said Bob Myers, co-founder and CEO.

Orbus Therapeutics Granted European Patent for Method of Use for Eflornithine

Retrieved on: 
Tuesday, September 28, 2021
Patent, Food, Therapy, Cancer, Anaplastic astrocytoma, European Patent Convention, Radiation, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Committee, European Medicines Agency, Glioma, FDA, Patient, Ornithine decarboxylase, EPO, GLOBE, CHMP, Derivative, Committee for Medicinal Products for Human Use, Company, Advanced Therapy Medicinal Product, PALO, Method, Opposition procedure before the European Patent Office, EMA, United Kingdom, Pharmaceutical industry

PALO ALTO, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Orbus Therapeutics Inc., a private, late-stage biopharmaceutical company focused on the development and commercialization of therapies that treat rare diseases, announced that it has been granted patent No. 3432872 entitled “Compositions and Methods for Use of Eflornithine and Derivatives and Analogs thereof to Treat Cancers, Including Gliomas,” by the European Patent Office (EPO).

Key Points: 
  • - Patent relates to method for use of eflornithine to treat cancers, including gliomas -
    PALO ALTO, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Orbus Therapeutics Inc., a private, late-stage biopharmaceutical company focused on the development and commercialization of therapies that treat rare diseases, announced that it has been granted patent No.
  • 3432872 entitled Compositions and Methods for Use of Eflornithine and Derivatives and Analogs thereof to Treat Cancers, Including Gliomas, by the European Patent Office (EPO).
  • The patent, which was granted on August 25, 2021 and is being validated in 15 European countries including Germany, France, Spain, the United Kingdom and Italy, covers eflornithine or a pharmaceutically acceptable salt thereof in a method for the treatment of temozolomide-recurrent anaplastic astrocytoma.
  • Orbus Therapeutics Inc. is a late-stage, private biopharmaceutical company that is dedicated to developing products that treat rare diseases for which there are few, if any, effective therapies.